CINQAIR

This brand name is authorized in United States. It is also authorized in Canada, Israel.

Active ingredients

The drug CINQAIR contains one active pharmaceutical ingredient (API):

1	Reslizumab UNII 35A26E427H - RESLIZUMAB
	Reslizumab is a humanised monoclonal antibody (IgG4, κ) against the human interleukin-5 (IL-5). Reslizumab binds specifically to IL-5 and interferes with IL-5 binding to its cell-surface receptor. IL-5 is a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. Reslizumab binds human IL-5 with picomolar affinity blocking its biological function; consequently survival and activity of eosinophils are reduced.
	Read more about Reslizumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CINQAIR Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R03DX08		R Respiratory system → R03 Drugs for obstructive airway diseases → R03D Other systemic drugs for obstructive airway diseases → R03DX Other systemic drugs for obstructive airway diseases
Discover more medicines within R03DX08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02456419
IL	מִשְׂרַד הַבְּרִיאוּת	7978
US	FDA, National Drug Code	59310-610